Novartis DRC An open-label first-in-human single ascending dose study to explore the safety, tolerability and efficacy of subretinal administration of CPK850 gene therapy in patients with retinitis pigmentosa caused by mutations in the RLBP1 gene
Research Grant
Administered By
Ophthalmology
Awarded By
Novartis Pharma AG
Start Date
June 4, 2018
End Date
January 30, 2026
Administered By
Ophthalmology
Awarded By
Novartis Pharma AG
Start Date
June 4, 2018
End Date
January 30, 2026